U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07209059) titled 'PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma' on July 03.
Brief Summary: This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic factors. The FINISH protocol (First-line Immuno-chemotherapy Navigated by Interim PET for Stratification and Hazard minimization In Hodgkin lymphoma) integrates nivolumab into induction therapy and tailors subsequent treatment based on interim PET-CT response. The study also includes exploratory monitoring of circ...